Drugs / OMN6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06087536 | May 2026 → Mar 2027 expected | bacterial pneumonia | Omnix Medical Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2024-05-10 | Omnix Medical Ltd | Results Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster) omnixmedical.com ↗
There were no serious adverse events or premature drop-outs. |
| 2024-02-20 | Omnix Medical Ltd | Regulatory Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6 omnixmedical.com ↗ |
| 2023-11-20 | Omnix Medical Ltd | Regulatory Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6 omnixmedical.com ↗
Omnix Medical , a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has approved a planned Phase II trial of the Company´s novel anti-infective OMN6. |
| 2023-07-09 | Omnix Medical Ltd | Regulatory OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office omnixmedical.com ↗
We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of infectious diseases. |
| 2023-05-10 | Omnix Medical Ltd | Results Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6 omnixmedical.com ↗
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced positive top-line results from the Phase I clinical trial of its lead compound OMN6, an anti-infective with a completely novel mechanism of action. |
| 2022-09-05 | Omnix Medical Ltd | Results STUDY: In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii omnixmedical.com ↗
Our Scientists at Omnix Medical have published a study demonstrating the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant Acinetobacter baumannii. |
| 2022-03-16 | Omnix Medical Ltd | Regulatory OMNIX MEDICAL ADVANCES NOVEL ANTI-INFECTIVE PROGRAM INTO CLINICAL DEVELOPMENT omnixmedical.com ↗
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced it received approval by Dutch authorities to initiate a Phase I clinical trial with its lead compound OMN6 in healthy volunteers. |
| 2021-04-11 | Omnix Medical Ltd | Results OMN6 A NOVEL BIOENGINEERED PEPTIDE FOR THE TREATMENT OF MULTIDRUG RESISTANT GRAM NEGATIVE BACTERIA omnixmedical.com ↗
In the following study, we present superior properties of an engineered antimicrobial peptide, OMN6, a 40‐amino acid cyclic peptide based on Cecropin A . . . |
| 2018-12-15 | Omnix Medical Ltd | Regulatory MAYA – CORPORATE ACTIONS omnixmedical.com ↗
OMN6, the company’s leading peptide, has been designated Qualified Infectious Disease Product (QIDP) by the US Food and Drug Administration (FDA)… |
All press releases naming this drug 12 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMN6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06087536 ↗ |
| Route | Intravenous | “3 x 3-hour IV infusions for 1 Day of treatment” NCT06087536 ↗ |